Malignant Thoracic Neoplasm — Trials

Malignant Thoracic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,775
Recruiting: 1,497
Ph III recruiting: 183
Growth YoY: +6.5%
Industry share: 36%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,528)

clinicaltrialsPublishedShowing 251–300 of 795 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02496663	Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor	active not recruiting	Phase 1	138	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT02535312	Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin	active not recruiting	Phase 1 / Phase 2	30	National Cancer Institute (NCI)